Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Waldenstrom Macroglobulinemia 2Sezary Syndrome 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Acute 2Leukemia, Monocytic, Acute 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, Erythroblastic, Acute 2Congenital Abnormalities 2Burkitt Lymphoma 2Skin Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Multiple Myeloma 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Leukemia, Promyelocytic, Acute 1Leukemia, Prolymphocytic 1Leukemia, Myelomonocytic, Juvenile 1

Interventions

denileukin diftitox 2Nivolumab 2sargramostim 1peginterferon alfa-2b 1Prednisone 1Phenobarbital 1Methylprednisolone Hemisuccinate 1Methylprednisolone 1Irinotecan 1Introns 1Infliximab 1Etoposide 1Dexamethasone 1Cyclosporine 1Cyclophosphamide 1Cisplatin 1Amifostine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Drug-Related Side Effects and Adverse Reactions × Methylprednisolone Hemisuccinate × Dermatologic × Clear all
NCT04305145 2026-01-29

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Massachusetts General Hospital

Phase 2 Active not recruiting
42 enrolled
Dermatologic

Colitis, Melanoma, Skin Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡